Hematologic oncology enters a transformative period
These are truly transformative times in the field of hematologic malignancies. Diseases that were once considered untreatable are now being managed—and in some
SOHO 2025
MDS News
SOHO 2025
Leukemia News
News
Don’t miss: AML session starts at 3:51 pm on September 3
Andrew Wei, MBBS, PhD, previews this year’s AML session starting at 3:51 pm today, September 3
Society Updates
SOHO reaches 10,000-member milestone
SOHO is excited to announce that we are now more than 10,000 members strong! Our members span the globe, and we thank them
Meeting News
SOHO 2025
SOHO 2025 program book available now
The Society of Hematologic Oncology has released the SOHO 2025 program book, detailing the Thirteenth Annual Meeting, set for September 3–6, 2025, at
Meetings / Conferences
SBBC
SOHO 2025
Society Updates
Building on a solid foundation to impact the future
In September 2012, the Society of Hematologic Oncology (SOHO) began with just 400 members and a vision to bring the knowledge of the
News
SOHO Insider Podcast
Drs. Kuykendall and Gerds discuss myelofibrosis anemia challenges
I put anemia near the top of the list, or at least an equal footing with spleen and symptoms,” Dr. Gerds said.
Leukemia
Chronic Lymphocytic Leukemia
Birelentinib granted Fast Track designation by FDA for CLL/SLL
The US Food and Drug Administration granted Fast Track Designation to birelentinib (DZD8586), a first-in-class lymphocyte-specific protein tyrosine kinase/Bruton’s tyrosine kinase (LYN/BTK) dual
Lymphoma
Aggressive B-Cell Lymphomas
ctDNA outperforms conventional measures in predicting remission after frontline LBCL treatment
Following frontline treatment for large B-cell lymphoma (LBCL), ultrasensitive circulating tumor DNA (ctDNA) is more prognostic of disease progression than conventional PET scans
Society Updates
SOHO EAGLE program takes off, expanding access to education globally
EAGLE, which stands for Exchange for Advanced Global Learning and Education, fulfills SOHO’s longstanding mission to educate and to expand global access to
News
SNDA submitted to FDA for venetoclax, acalabrutinib combo in CLL
The US Food and Drug Administration (FDA) received the supplemental New Drug Application for venetoclax (VENCLEXTA) and acalabrutinib (Calquence), an all-oral, fixed-duration regimen,